Differences

This shows you the differences between the selected revision and the current version of the page.

public:ccsip:optical_biopsy 2010/11/24 00:13 public:ccsip:optical_biopsy 2010/11/24 11:10 current
Line 1: Line 1:
-====== Optical Biopsy Theme ======+====== Optical Biopsy (Tissue level) Theme ======
===== Description of the Technology ===== ===== Description of the Technology =====
Line 5: Line 5:
==== Basic modalities ==== ==== Basic modalities ====
-Point Spectroscopy +  * Point Spectroscopy 
- Reflectance & Fluorescence +     * Reflectance & Fluorescence 
- Spatially Resolved +     * Raman 
- Polarized +     * IR 
- Time Domain  +     * Spatially resolved, Time Domain, Polarized
- Raman +
- IR +
-In Vivo Microscopic Imaging +
-        Confocal Reflectance & Fluorescence Microscopy +
-        Multi Photon Microscopy +
-        Optical Coherence Tomography +
==== Current research in the group ==== ==== Current research in the group ====
-Haisha Zheng: Raman, Reflectance and Fluorescence Spectroscopy (Skin, Lung, GI)+**UBC: Calum MacAulay, Haisha Zheng, Pierre Lane**: \\  
 +Raman, Reflectance and Fluorescence Spectroscopy, In vivo confocal microendscopy, multi-photon\\  
 +Anatomical Location: Skin, Lung, GI, Cervix\\
-Calum MacAulay: OCT, reflectance and fluorescence spectroscopy, In vivo confocal microendscopy (Lung, Oral, Cervix, GI)+**McMaster: Qiyin Fang, Joe Hayward, Tom Farrell, Mike Patterson**: \\  
 +Time-resolved fluorescence spectroscopy & imaging, Diffused Reflectance + TRF; \\  
 +Anatomical Location: Brain, GI, Lung\\  
 + 
 +**UCLA: Warren Grundfest, William H. Yong** \\ 
 + 
 +**UC Irvine: **
-Pierre Lane: OCT, reflectance and fluorescence spectroscopy, In vivo confocal microendscopy (Lung, Cervix, Ovarian) 
===== Challenges ===== ===== Challenges =====
Line 30: Line 30:
Identifying opportunities/indications needing/requiring immediate clinical action (see and treat methodology) since in the genomic age if a biopsy can be taken it will be for conventional pathology (current practice) and genetic/genomic analysis (future studies) Identifying opportunities/indications needing/requiring immediate clinical action (see and treat methodology) since in the genomic age if a biopsy can be taken it will be for conventional pathology (current practice) and genetic/genomic analysis (future studies)
-==== Significant clinical prblems ====+==== Significant clinical problems ==== 
 +Brain, Heart, etc (tissues for which biopsy entails significant clinical risk) 
 + 
 +Screening settings in which low specificity of primary test could result in too frequent biopsy which induces costs or morbidity (Oral, Skin, etc)
==== Key technology barriers ==== ==== Key technology barriers ====
Line 39: Line 42:
==== potential industrial partners ==== ==== potential industrial partners ====
 +
 +===== References =====

Navigation
Personal Tools